Psychiatr. praxi. 2021;22(2):105-108 | DOI: 10.36290/psy.2021.021

Brexpiprazole as a suitable alternative to LAI

MUDr. Jan Čermák
Psychiatrie Říčany, s. r. o.

New partial dopamine agonists promise a balance between good efficacy and a favorable spectrum of side effects in the treatment of schizophrenia. They are suitable drugs to solve the metabolic syndrome caused by other types of antipsychotics. We successfully transferred a patient from 210 mg depot olanzapine to 4 mg brexpiprazole. Brexpiprazole has very low discontinuation rates due to side effects and is therefore a possible alternative in cases where we cannot choose from other antipsychotics available for injection.

Keywords: olanzapine, metabolic syndrome, brexpiprazole.

Published: July 9, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Čermák J. Brexpiprazole as a suitable alternative to LAI. Psychiatr. praxi. 2021;22(2):105-108. doi: 10.36290/psy.2021.021.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Pillinger T, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry 2020; 7: 64-77. Go to original source... Go to PubMed...
    2. Leucht S, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet Psychiatry 2013 Sep 14; 382(9896): 940. Go to original source... Go to PubMed...
    3. Citrome L. Activating and sedating adverse effects of second-generation antipsychotics in the treatment of schizophrenia and major depressive disorder. J Clin Psychopharmacol 2017; 37: 138-147. Go to original source... Go to PubMed...
    4. Frankel JS, Schwartz TL. Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Ther Adv Psychopharmacol 2017; 7(1) 29-41. Go to original source... Go to PubMed...
    5. Maeda K, et al. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther 2014; 350(3): 589-604. Go to original source... Go to PubMed...
    6. Correll CU, et al. Efficacy of brexpiprazole in patients with acute schizophrenia: Review of three randomized, double-blind, placebo-controlled studies. Schizophrenia Research 174(2016): 82-92. Go to original source... Go to PubMed...
    7. Citrome L. Aripiprazole, brexpiprazole and cariprazine: Not all the same. Current Psychiatry 2018; 17: 24-33, 43.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.